Agreement on Access and Benefit Sharing for Non-Commercial Research




This document contains a sample agreement on mutually agreed terms (MAT) for Access to Genetic Resources and Sharing of Benefits, for the use by providers and non-commercial academic researchers.

At the same time it provides a sample for the potential of model clauses within a sector specific approach; as comprised in Art. 15 of the Draft Protocol on ABS under the CBD.1

The agreement aims at creating transparent, and legally secure relations that are appropriate to the needs and intentions of all parties involved. The suggested terms and clauses are intended to meet the needs of both the providers of the genetic resources and the researchers seeking access. The agreement proposes language to ensures fair and equitable sharing of benefits.








The agreement may be considered for use in various scenarios of access and benefit sharing, such as inventories of biodiversity; research in systematics, ecology and evolution; identification and isolation of active compounds; and genetic research.






The Agreement is adapted to the specific situation of non-commercial research sponsored by public funding. Its basic premise is that the Mutually Agreed Terms, as stipulated in CBD Art 15, are a bilateral contract concluded between providers and users, resulting from their fair negotiations on the terms of access and benefit sharing.






Involved parties are encouraged to take account of each others specific needs and circumstances, reflecting on the type of envisaged research (e.g. ecological vs. phytopharmacological research) and the specifics of the research (e.g. difficulties in identifying taxa, sharing of material). For the provider, this may include means to monitor the use of genetic resources.




We assumed the following basic scenario:

The resources are accessed by a researcher under the lead and responsibility of a research institute.

The research is non-commercial, aiming at providing publicly available results. The results have therefore to be published.

Unexpected research results may trigger reflections towards their utilisation in a commercial context.

Benefits are non-monetary as a rule. They usually accrue during the research process.

Genetic resources might be transferred to third parties under a framework of customary cooperation by research institutes.








The analysis of research types and access situations carried out by the ABS-team led to the following conclusions:




  1. One of the challenges in implementing the ABS system consists in controlling the flow of the acquired resources throughout the value chain, especially in the user country. At the centre of the problem lies the risk that the resources and related information accessed under the conditions for non-commercial intent enter the R&D sector without corresponding MATs for potential commercial developments.


  1. ABS システムを実行する際の課題の1つは、利用国のバリュー チェーン全体の流れの中で、取得した遺伝資源の流れを制御することである。問題の中心として、非商用目的という条件の下でアクセスした遺伝資源や関連情報が、潜在的な商用開発に対応する相互合意もなく、研究開発セクターに移されるというリスクがある。


  1. Non-commercial researchers depend largely on public funding. For continued financial support the publication of research results is a crucial step and has to happen in a timely manner. Scholarly standards for disclosure of information for scientific transparency and the exchange of material among peers may collide with the need of providers to control the use of genetic resources. In turn, too strict control measures could put research at stake.


  1. 非営利研究の研究者は、大部分は公的資金に依存している。継続的な資金援助を得るために、研究成果の出版の重要なステップで、タイムリーに行わなければならない。科学的な透明性のための情報の開示と研究者間の研究材料の交換に対する学術的な基準は、遺伝資源の利用を制御する提供者の必要性と相反するところがある。逆に言えば、あまりにも厳しい規制措置は、研究を危険にさらすことになる。


  1. Different fields of research with genetic resources imply different degrees of probability that the research results flow (intentionally or unintentionally) into the commercial value chain. It is, however, essential to realize that some fields of research show very low probability, for example the elaboration of biodiversity inventories or ecological studies. In such cases the providing country could require less control over the uses and instead request periodic reports on research progress to monitor the user?fs compliance with the MATs.
  1. 遺伝資源を用いる研究のさまざまな分野には、意図的か意図しないかにかかわらず、研究成果を商業的価値チェーンに流し込む、異なった度合の可能性を含んでいる。しかし、例えば、生物多様性目録または生態学的研究の精緻化の例のように、ある分野の研究は非常に低い可能性であることを認識することが不可欠である。このような場合、提供国は、利用に対して制御を低くする必要があり、代わりに、利用者の相互に合意する条件の遵守を監視するために、研究の進捗状況の定期な報告を求めるべきである。


The Agreement takes account of various research activities by proposing options for the following conditions:


1. Different situations (e.g. access to genetic resources vs. access to related traditional knowledge; access to specified taxa vs. the need to identify the samples after collection);


2. Different models of research cooperation; and diverse needs to monitor the implementation of the agreement;


3. Specific aspects of academic research, such as the need to publish results and the exchange of data, storage and accessibility of samples etc.




1. 遺伝資源へのアクセス、伝統的知識へのアクセス、特定の分類群へのアクセス、収集後にサンプル同定が必要な場合などの異なった状況


2. 異なった共同研究形態、契約実施の監視に対する様々なニーズ


3. 成果の報告出版の必要性、データ交換の必要性、試料の保存と第三者利用可能性など学術研究の特徴

How to use the Agreement


The Agreement on Access to Genetic Resources and Sharing of Benefits (ABS) for Non-commercial Academic Research containing Model Clauses is based on the conviction that mutually agreed terms are a contract that needs to be negotiated and concluded between the parties, i.e. the providers and the users of genetic resources. The proposed Agreement provides a tool-box for composing a contract on mutually agreed terms tailored to accommodate the needs of the stakeholders. We recommend that both parties possess the full text of the Agreement in order to foster discussions on options and provide solutions to disagreements that might arise.






The Agreement consists of different types of clauses:

1) General clauses, like the preamble, or the definition of the purpose (article 4);

2) Clauses on substantive issues (articles 5 to 17);

3) Clauses on procedural issues.


Most of the clauses on substantive issues offer a basic clause (marked green in the sample agreement) and include options that can be added to the basic clause or used as a stand-alone solution. Other clauses offer only options to choose from as needed.


1)前文や目的 (第 4 条) の定義のような一般的な条項

2)本質的な問題に対する条項 (第5 条から第 17条)




本質的な問題に関する条項の大部分について、 (サンプル契約の中ではグリーン マーク) 基本的な条項を提供する。基本的な条項に追加または独立した解決策として使用することができるオプション条項がある。他の条項は、必要に応じて、選択可能なオプションのみを提供している。


In drafting the Agreement, we intended to cover most issues that might arise in the relationship between providers and non-commercial public researchers. The basic clauses by themselves may form a full contract for simple non-commercial research situations. Not all cases will need all clauses; each agreement must be modelled according to the specific needs of the parties engaged in the negotiations. The Agreement is therefore made freely available as Word Document under a Creative Commons Licence that allows for changes in the document.






The purpose of this Agreement is to set out the conditions for the use of genetic resources, any associated Traditional Knowledge (TK) and the sharing of resulting benefits between the parties concerned in accordance with the Convention on Biological Diversity (the CBD), particularly in respect with the principles established under its Articles 1, 8(j), 15, and the Bonn Guidelines.



生物多様性条約(CBD)、特にその第1条、第8(j)条、第15条と、ボン・ガイドラインのもとで確立された原則に従って、この契約の目的は、遺伝資源、それに付随する伝統的知識 (TK)の利用と、結果として得られる利益の関連する当事者間の配分の条件を設定することある。


The Agreement contains Mutually Agreed Terms (MAT) according to Article 15.7 CBD.


契約には、生物多様性条約第15.7条に従って、相互に合意した条件 (MAT) を含む。


The Agreement is designed to promote non-commercial academic research, such as research in taxonomy, ecology, biochemistry and genetics, and to foster conservation and the environmentally sound and sustainable use of genetic resources.




Its objective is to provide a sound basis for cooperation, transparency, communication and trust between the parties to the Agreement, taking account of the concerns of both providers and users of genetic resources.


1. Parties to the Agreement


The Agreement is entered into on [insert the date] by and between


[insert the name and details of the following:


..State and Institution (competent ABS national authority)


..The contact person responsible for the implementation of the Agreement on behalf of the institution]


together hereinafter referred to as the Provider.




[insert the name and details of


..The responsible research institution


..The representative of the research institution responsible for the implementation of the Agreement]


Represented by the authorized head or member of the research team; authorized researcher [insert the name and details of researcher].


together hereinafter referred to as the “User”.


1. 本契約の合意者























2. Prior Informed Consent


Option 2.1


The Agreement is based on the Prior Informed Consent (PIC) issued beforehand by the Provider to the User for the access to the genetic resources concerned. The PIC document is attached to this Agreement and is consid­ered an integral part of the Agreement.


2. 事前の情報に基づく合意






Option 2.2


The Provider hereby confirms that he/she has been informed on the research project by the User and con­sents to provide access to genetic resources in situ and/or ex situ necessary to carry out the research in accordance with the research project attached to this Agreement.






3. The Purpose of the Agreement


The purpose of this Agreement is to specify the terms for

1. Accessing genetic resources,

2. Their utilization in accordance with the PIC,

3. Their possible transfer to third parties, and

4. For sharing the benefits resulting from the utilization of genetic resources.


3. 本契約の目的








4. Terminology


In this Agreement the terms defined in Article 2 CBD shall have the same meaning, unless otherwise defined in this article.






4.1 Genetic Resources

Genetic Resources means genetic material of actual or potential value.


4.1 遺伝資源



Option 4.1.1


Genetic Material means any material of plant, animal, microbial or other origin containing functional units of heredity.





Option 4.1.2


The term “Genetic Material” includes living and dead resources.





Option 4.1.3


The term “Genetic Material” includes derivatives as defined below.





4.2. Derivatives


Option 4.2.1


Derivatives means products based on Genetic Resources and generated through techniques such as expression, replication, characterization or digitalization.


4.2. 派生物






Option 4.2.2


Derivatives mean substances created from Genetic Resources that are substantially modified to have new properties.





4.3 Commercialization


Commercialization means the use of the Genetic Resource for the generation of any kind of actual or potential economic profit.

It means in particular any sale, lease, licensing of the Genetic Resource, and/or Products generated from its use through actions such as filing a patent application, obtaining intellectual property rights or other tangible or intangible rights.

It includes any transfer of the Genetic Resource to a for profit organization.


4.3 商用化






4.4 Mutually Agreed Terms (MAT)


The Mutually Agreed Terms are an agreement negoti­ated between the Provider and the User of the Genetic Resources and/or holders of Traditional Knowledge associ­ated to the Genetic Resources according to the national law of the country providing the resources. The MAT regu­late conditions for the access to the Genetic Resources and to their associated Traditional Knowledge and the fair and equitable sharing of benefits that result from their use. They are adapted to the specific access situation.


4.4 相互に合意する条件(MAT)




4.5 Traditional Knowledge


Option 4.5.1


Traditional Knowledge is the accumulated knowledge that is vital for the conservation and sustainable use of biological resources and/or which is of socioeconomic value, and which has been developed over the years in indigenous/local communities.


4.5 伝統的知識






Option 4.5.2


Traditional Knowledge means “information or indi­vidual or collective practices of an indigenous or local community associated with the genetic heritage having real or potential value”.





4.6 Prior Informed Consent (PIC)


Prior Informed Consent means the unilateral declara­tion of the Provider that he/she has been informed about the planned research and that he/she is willing to provide the required access to the Genetic Resource.

4.6 事前の情報に基づく同意




4.7 Product


Product means the result produced, obtained, extracted or derived from the Genetic Resource through research or research & development (R&D) activities, including data and information generated through analyses of the Genetic Resources.

4.7 製品




4.8 Progeny


Progeny means unmodified offspring from the Genetic Resource

4.8 子孫



4.9 Third Party


Third Party means any person or institution other than the Provider, the User and any collaborator under their control or supervision. A Third Party is not bound to the terms and conditions of this Agreement unless other­wise agreed with the User.


4.9 第三者機関




4.10 Unauthorized Person


Unauthorized Person means any person that came into possession of the Genetic Resources without the authorization of the User.


4.10 許可されない者




5. Genetic Resources to be accessed


The User shall have access to the following Genetic Resource(s):

[Insert list of the Genetic Resources to be accessed].



5. アクセス可能な遺伝資源




Option 5.1


Since the species/strains present at the collection site are not know to the User at the time of concluding this Agreement, a general account of species/strains most likely to be collected is given in Annex XX.

A list of the collected samples according to the research­er’s field-notes is presented to the Provider within XX months after having gathered the samples.



本契約の締結時に、実際の採取地で存在する種/系統を利用者に知らされていないので、採取する可能性が最も高い種/系統の一般的な説明を別添 XXに示される。研究者のフィールドノートに基づく収集したサンプルのリストは、サンプル収集後XXヶ月以内に提供者に示される。


Option 5.2


If the collected samples cannot be identified in the list of collected samples within the above prescribed peri­od, their identification has to be shared with the User as soon as it is available.






6. Utilization


The Material may be utilized for non-commercial pur­poses including for academic research and collections, and for training, teaching and education.

The User must comply with the User’s and Provider’s national regulations and with relevant international law. The utilization of the Material or derived informa­tion for any type of Commercialization is prohibited.


6. 利用




Option 6.1


The Genetic Material shall be used exclusively for the following purposes: [insert allowed activities and/or uses].




7. Change in Utilization from Non-commercial to Commercial


The Commercialization of the Genetic Material and related information is prohibited. Any change in utilization from non-commercial to com­mercial shall require a new Prior Informed Consent in writing issued by the Provider. In this case, the terms of such Commercialization shall be subject to a separate agreement (MAT) between the involved parties.


7. 非商用から商用への利用変換




8. Transfer of Genetic Resources (and associated TK) to Third Parties


Transfer of the Genetic Resources for the purposes of academic research and collections, and for training, teaching and education, or any other non-commercial activities is allowed under the condition that the User ensures that the subsequent person or institution (Third Party) is informed about the provisions under this Agree­ment and undertakes to pass on the Genetic Resources under the same obligations to any further recipient.

8. 第三者機関への遺伝資源とそれに付随する伝統的知識の移転


学術研究とコレクション、トレーニング、教育と指導、またはその他の非商用活動を行うために、遺伝資源の移転は、本契約の利用者が保障する条件下で、許可される。その条件とは、以降の研究者または機関 (第三者機関) が、本契約の規定を通知され、更なる移転者に渡す場合に、同様の義務の下で遺伝資源を移転することを約束する場合に限られる。


Option 8.1

The User delivers to the Provider annually a list of the Third Parties to whom the Genetic Resource was trans­ferred to.




Option 8.2

The User shall maintain retrievable records of any trans­fer of the Genetic Resources to Third Parties under the conditions corresponding to this Agreement.




Option 8.3

The User shall require the Third Party to sign an agree­ment containing identical obligations on Use and Trans­fer of the Genetic Resources (and associated TK) as set out in this Agreement.



利用者は、第三者機関に対して、本契約で設定された遺伝資源 (および関連する TK)の利用と移転に関する同一の義務を含む契約書に署名することを要求しなければならない。


Option 8.4

The Genetic Resources [and their associated TK] may be transferred to Third Parties only after having obtained the written consent of the Provider and in accordance with Mutually Agreed Terms between the Provider and the Third Party. Excempted is a temporary transfer of the Genetic Resource to taxonomic specialists for scien­tific identification.



遺伝資源(とその関連する TK)は、提供者による書面による同意と、提供者と第三者機関の間の相互に合意した条件に従っての書面による同意を得たあとでのみ第三者機関に転送可能となる。科学的同定のために分類学的専門家への遺伝資源の一時的な移転は例外とされる。


Option 8.5

The User is entitled to deposit the Genetic Resources in collections that are accessible without restrictions for research purposes such as herbaria, museums and cul­ture collections.




Option 8.6

If the Genetic Resources are transferred to an ex situ collection of living Genetic Resources for educational purposes (such as zoos, botanic gardens), this institu­tion is – in addition to the obligations of this Agreement – obliged to take any appropriate precautions to pre­vent the Genetic Resource coming into the possession of any Unauthorized Person.





Option 8.7

If the use or storage of the Genetic Resource is subject to special conditions or restrictions, such conditions/ restrictions have to be clearly indicated on the label or otherwise linked to the sample, when transferring the Genetic Resource to Third Parties, including the indica­tion of where the information concerning the special conditions/restrictions can be found.





9. Benefit Sharing

The benefits arising from the access and use of the Genetic Resources shall be shared fairly and equitably by the User, in accordance with the principles estab­lished in the CBD. Basic benefits to be shared include:


9. 利益配分



1. The offer to the Provider to include local researchers in the research activities, if such interest exists. 1. 関心がある場合、研究活動へ地域の研究者を参加させるよう提供者に申し出ること
2. In case of publications or oral presentation of the research results, full acknowledgement is to be given to the source of the Genetic Resource; 2. 研究結果の出版や口頭発表に場合、遺伝資源の源(source)に対して最大限の謝辞を表明する。
3. If TK associated to the Genetic Resources is involved, the research results published or presented orally will include full acknowledgement of the source of the Genetic Resources and the TK, if so required by the providers. 3. 遺伝資源に付随する伝統的知識がある場合、研究結果の出版や口頭発表は、もし、提供者によって要求されたなら、遺伝資源と関連する伝統的知識のSourceに最大限の謝辞を含める。
4. The Provider will receive a copy of all publications; 4. 提供者はすべての出版のコピーを保有する。
5. Research results will be communicated to involved stakeholders (e.g. communities, indigenous people) in an adequate manner and according to reasonable requirements of the Provider; 5. 研究の結果は、適切な方法で、かつ提供者の合理的な要求に従って、地域社会や先住民などの利害関係者に伝達される。
6. If applicable, share duplicate specimens with the repository in the Provider country in accordance with good scientific practice.In addition, the User agrees to share the following ben­efits:

[Choose from the list of benefits appended to this Agreement; insert a detailed lists of benefits here or in an annex]


6. 必要に応じて、優れた科学的習慣に従って、提供国のリポジトリと標本を重複して保存する。更に、利用者は次の利益を配分することに同意する。



10. Rights and Obligations of the Provider


The Provider defined in Article 1 is the responsible con­tact point for the User for the entire duration of the present Agreement.

The Provider has the obligation to facilitate access to the Genetic Resources. This includes the facilitation of the acquisition of other permits required in accordance with the relevant national or regional regulations in the Provider country as well as export permits.

10. 提供者の権利と義務





Option 10.1


The Provider designates the following institution [insert the relevant institution] as the responsible contact point for the User for the entire duration of the present Agreement.

Contact details of the technical contact point are pro­vided in Annex [XX] to this Agreement.

The Provider has the right to receive information on the state of the research from the User as agreed upon (see Article 12 on Reporting).






Option 10.2


The Provider requests that the following analytical parts as set out in the project are performed in the providing country: [insert a list of analyses to be performed in the Provider’s country].

The Provider confirms that all necessary conditions (equipment, staff and consumables) for conducting the analyses are available;

The User confirms that he/she has the necessary resources (funding, time) for such an arrangement.








11. Rights and Obligations of the User


The User is entitled to administrative support and guid­ance to facilitate the acquisition of the necessary per­mits required by the Providing country.

The User shall not use the Genetic Resource nor deriva­tives generated in the research for any commercial purposes, nor shall the User commercialize any Prod­uct derived from the Genetic Resource, unless with the written consent of the Provider.

The User is obliged to take all reasonable precautions to prevent the Genetic Resource coming into the posses­sion of any Unauthorized Person.

The User is obliged to inform the Provider about any unforeseen research results that are of potential com­mercial interest, prior to any disclosure of this informa­tion to the public.


11.  利用者の権利と義務







Option 11.1


If the research implies TK associated to the Genetic Resource, the User is obliged to respect any relevant international law and the national and regional regu­lations in the Provider’s country, and has to proceed according to the instructions of the Provider. In any case the User is obliged to respect the customary law of the holders of the TK and has to apply ethical standards.

オプション 11.1


研究が、遺伝資源に関連した TK を含む場合は、利用者は、関連する国際法と提供国の国や地域の規制を尊重する義務がある。提供者の指示に従って行動する必要がある。いかなる場合においても、利用者は TK の所有者の習慣法を尊重する義務があり、倫理基準を適用する必要がある。


Option 11.2


Corresponding to national law the User will conclude an ancillary contract with the holders of TK and/or the private land owners of the genetic resources.

The ancillary contract forms an integral part of this Agreement.

オプション 11.2


国内法に従えば、利用者は、TK の所有者、および/または、遺伝資源のある民間の土地所有者と補助的な契約が締結される。補助的な契約は、本契約の必須の部分を形成する。


12. Data Sharing


The User agrees that the Provider has the right to access the following data resulting from the research:


The User shall facilitate access to the above defined data for the Provider.

The Provider agrees that for using the data in his own research, he needs the consent of the User.

12. データの共有







Option 12.1


Given the cooperative approach to the research, the Provider and the User agree in a separate agreement on the use of the data, annexed to this Agreement [Annex XX] and forming its integral part.






13. Reporting


The User will deliver a written report in accordance with the Provider´s instructions as to its structure, informa­tion included, etc, upon his/her request.


13. 報告





Option 13.1


The User shall submit an annual written report on the research accomplished.

オプション 13.1




Option 13.2


Upon request of the Provider, the User submits a writ­ten report on the research accomplished.

オプション 13.2




Option 13.3


Upon request of the Provider, the User submits an annual written report on the research accomplished. The report shall include a list of Third Persons to whom the Genetic Material has been transferred.

オプション 13.3




Option 13.4


Since the Provider is a private citizen, upon his/her request, the report is translated into the local language by the User and adapted to a non-scientific audience.


プション 13.4




14. Intellectual Property Rights


The User shall not claim any intellectual property rights over the Genetic Resource in the form received.


If the User wants to obtain intellectual property rights on research results such act shall be treated as change in utilization and thus shall be regulated under Article 7 of the present Agreement.


If the Provider wishes to obtain IPR on research results, such act shall be treated as change in utilization and shall be regulated under Article 7 of the present Agree­ment. In particular the ownership of the IPR and the distribution of the value derived from the IPR are to be negotiated.


14. 知的財産権




利用者が研究成果について知的財産権を取得したい場合、そのような行為は、利用の変更とみなされ、本契約第7条 の下で規制しなければならない。


利用者が研究成果について知的財産権を取得したいと希望する場合、そのような行為は、利用の変更とみなされ、本契約第7条 の下で規制しなければならない。特に、知的財産の所有権と知的財産から派生する価値の分配は交渉事項となる。


15. Publications


The User has the right to publish the results of the research related to the Genetic Resource according to Article 6 of the present Agreement, and according to good scientific practice. The origin of the Genetic Resource has to be acknowledged.


15. 出版




Option 15.1


The User has the right to publish the results of the research related to the Genetic Resource according to good scientific practice. The origin of the Genetic Resource has to be acknowledged, as well as the sourc­es of TK associated with the Genetic Resource.






Option 15.2


The holder of TK associated to the Genetic Material has the right to request confidentiality of specific informa­tion [describe the information subject to confidentiality] such as for spiritual reasons; to prevent the depletion of the genetic resources; and/or to prevent unsafe/hazard­ous applications of the TK in the health sector.





Option 15.3


If the User, in the course of the research, discovers any unforeseen commercial potential of the Genetic Materi­al, he/she is obliged to share such information with the Provider prior to any publication of such information.

If the Provider intends to pursue a potential commer­cialization, this is subject to negotiations between the Provider and the User according to Article 7. The Pro­vider agrees not to hold up the User’s research work unless concerns are concrete and justified in terms of well-defined proprietary interest.






Option 15.4


If the User is prevented from publishing the results of the research due to the Provider’s wish to obtain a pat­ent over the research results, the Provider shall file the patent application within [XX] months. After the agreed period, if the Provider has failed to file a patent applica­tion, the User has the right to proceed with the publica­tion of the research.




研究結果に対して特許を取得したいという提供者の意志のため、利用者が研究成果を公開するのを禁止された場合、提供者は[XX] ヶ月以内に特許出願を提出しなければならない。提供者が特許出願提出をしなかった場合、合意された期間の後、利用者は研究成果の公開を続ける権利がある。


16. Handling of the Genetic Material after Termination of the Agreement


Upon completion of the project, Genetic Material will be stored or disposed of according to the utilization agreed under Article 6.


16. 契約の満了後の遺伝物質の取り扱い




Option 16.1


If the Genetic Material has been placed in storage, or in public collections, upon expiration of the Agreement or its termination, the Genetic Material may be available for use only under the same conditions as contained in this Agreement.





17. Duration and Termination of the Agreement


The present Agreement shall end on [insert the date] and may be renewed upon the mutual agreement of the Parties.

17. 契約の満了期間




Option 17.1


The present Agreement shall be deemed to be in force until the Genetic Material is returned to the satisfac­tion of the Provider upon completion of the Project. Regarding the Genetic Material related information, the present Agreement shall be subject to any associated rights, such as copyright or trade secrets.


オプション 17.1




Option 17.2


When a Party to the present Agreement wants to ter­minate the Agreement prior to the completion of the Project, the Party shall give written notice [XX] months in advance. The present Agreement may be terminated at any time by mutual agreement of the Parties. The present Agreement may be terminated immedi­ately, in case of its breach.

オプション 17.2


プロジェクトの完了の前に、本契約の片方の当事者が、本契約を終了したいと希望する時、その当事者は、[XX] 箇月前に書面による通知をしなければならない。本契約は、当該当事者の合意によって、いつでも終了可能である。本契約に違反がある場合、本契約は直ちに終了される可能性がある。


18. Settlement of Disputes


The Parties agree to make attempts in good faith to negotiate the resolution of any disputes that may arise under this Agreement. If the Parties are not able to resolve a dispute within a period of [XX] months, such dispute shall be finally settled by an arbiter to be mutu­ally agreed between the Parties.

18. 紛争解決


当該当事者は、本契約下で生じるすべての紛争の解決に誠意をもって交渉しようとすることに合意する。当該当事者が、[XX] ヶ月の期間内に紛争を解決できない場合は、当事者間で合意する調停者によって最終解決されるものとする。


Option 18.1


If the Parties are not able to resolve any dispute within a period of [XX] months, such dispute shall be resolved before the [XXXX] Court law as the only competent body for resolving disputes arising under this Agree­ment and in accordance with [XXX].

[Insert applicable Law; Jurisdiction]


オプション 18.1


当該当事者が、[XX] ヶ月の期間内にすべての紛争を解決できない場合、そのような紛争は、本契約と[XXX]に従って、発生した紛争を解決する唯一の審査権を有する機関として [XXXX] 裁判所法のもとで解決されなければならない。



19. Other Provisions 19. その他の条項


Copyright © National Institute of Genetics ABS Support Team for Academia All Rights Reserved.